Combination of sacubitril/valsartan and blockade of the PI3K pathway enhanced kidney protection in a mouse model of cardiorenal syndrome.

Shunichiro TsukamotoHiromichi WakuiTatsuki UeharaYuka ShibaKengo AzushimaEriko AbeShohei TanakaShinya TaguchiKeigo HirotaShingo UrateToru SuzukiTakayuki YamadaSho KinguchiAkio YamashitaKouichi Tamura

Published in: European heart journal open (2023)

PI3K pathway activation has been identified as a key mechanism affecting remnant kidney injury under ARNI treatment in CRS pathology, and blockading the PI3K pathway with simultaneous ARNI treatment is a potential therapeutic strategy for treating CRS with overt albuminuria.

Keyphrases

mouse model
combination therapy